Sorry, you need to enable JavaScript to visit this website.

Newly Diagnosed: D + RD Study | DARZALEX® IV (daratumumab)

DARZALEX® Clinical Studies

DARZALEX® in combination with Revlimid®
(lenalidomide) + dexamethasone

DARZALEX® was studied in combination with Revlimid® + dexamethasone (Rd) vs Rd alone in 737 patients with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant).

The main goal of the study was to measure the length of time patients lived without their multiple myeloma getting worse.

Another goal was to measure overall response rate, which is the percentage of patients who responded to treatment.

Clinical study results: DARZALEX® + Rd vs Rd alone

DARZALEX® in combination with Rd increased the time patients lived without their multiple myeloma getting worse.

74percent

of patients treated with DARZALEX® + Revlimid® +
dexamethasone (DRd) (n=368) lived without their disease getting
worse vs 61% of patients treated with Rd alone (n=369).*

*At a median follow-up of 28 months.

More patients responded to DARZALEX® in combination with Rd vs Rd alone

9outof10

93% of patients responded to DARZALEX® + Revlimid® + dexamethasone vs 81% of patients treated with Rd alone.

Learn how this DARZALEX®  treatment regimen is given